PLEASANTON, Calif. and PARIS, Nov. 6, 2023
/PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG),
announce they have entered into an agreement to add 10x Genomics
spatial omics and single-cell technologies to the ambitious MOSAIC
project, which has already garnered attention for its pioneering
work in tumor analysis for therapeutic discovery.
Unveiled in June 2023, MOSAIC is a
landmark $50 million project that
leverages spatial omics technologies to map tumor structures at
single-cell resolution, encompassing an astounding 7,000 tumor
samples—100 times larger than any comparable dataset. With the
addition of 10x Genomics' state-of-the-art Visium technology for
spatial transcriptomics and leading Chromium portfolio for
single-cell analysis, MOSAIC is poised to unlock transformative
discoveries in the battle against cancer, unveiling unprecedented
insights into tumor and immune cell interactions.
"Spatial omics, combined with deep multimodal patient profiling,
will revolutionize our understanding of cancer biology. I am really
excited that the MOSAIC study will use the 10x Visium and Chromium
platforms to generate spatial and single-cell transcriptomics for
thousands of cancer patients. Powered by Owkin's unique AI, and the
collective expertise of our partners, such data is a unique asset
to mine for novel targets, understanding patient response and
resistance to current treatments and ultimately to develop new
therapies for cancer patients," said Eric
Durand, SVP Data Science at Owkin.
Jim Wilbur, Chief Commercial
Officer at 10x Genomics, said, "We're thrilled to have our leading
technologies take on such an important, enabling role in the MOSAIC
study. With the addition of 10x, the distinguished team of MOSAIC
researchers will have access to world-class single cell and spatial
tools. We're confident our technology platforms will enable the
exceptional quality data required to fulfill the project's
ambitious mission. The ability to glean single-cell and spatial
information from thousands of patient samples and analyze them at
scale with Owkin's powerful AI technology will have a profound
impact that has the potential to transform the future of cancer
care."
About MOSAIC
MOSAIC is a global initiative uniting top academic centers and
industry partners to create the world's largest spatial omics and
multimodal dataset in oncology. Through the convergence of
large-scale spatial omics data and AI, MOSAIC will power the next
revolution in cancer research, bringing about the identification of
novel treatment response and resistance mechanisms, new patient
subtypes, and biomarkers for prognostics and diagnostic patient
stratification.
About Owkin
Owkin is a TechBio company that combines the best of human and
artificial intelligence to ensure every patient gets the right
treatment. By understanding complex biology through AI, we identify
new treatments, de-risk and accelerate clinical trials and develop
AI diagnostics. Owkin uses privacy-enhancing federation to access
up-to-date multimodal patient data that unlocks AI's potential to
power precision medicine. We merge wet lab experiments with
advanced AI techniques to create a powerful feedback loop for
accelerated discovery and innovation. Owkin founded MOSAIC, the
world's largest multi-omics atlas for cancer research. Owkin has
raised over $300 million through
investments from leading biopharma companies (Sanofi and BMS) and
venture funds (Fidelity, GV and BPI, among others)
Contacts
Media: edward.farmer-ext@owkin.com
About 10x Genomics
10x Genomics is a life science technology company building products
to accelerate the mastery of biology and advance human health. Our
integrated solutions include instruments, consumables and software
for single cell and spatial biology, which help academic and
translational researchers and biopharmaceutical companies
understand biological systems at a resolution and scale that
matches the complexity of biology. Our products are behind
breakthroughs in oncology, immunology, neuroscience and more,
fueling powerful discoveries that are transforming the world's
understanding of health and disease. To learn more,
visit 10xgenomics.com or connect with us on
LinkedIn or X (Twitter).
Disclosure Information
10x Genomics uses filings with the Securities and Exchange
Commission, our website (www.10xgenomics.com), press releases,
public conference calls, public webcasts and our social media
accounts as means of disclosing material non-public information and
for complying with our disclosure obligations under Regulation
FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/owkin-integrates-10x-genomics-spatial-omics-and-single-cell-technologies-to-the-mosaic-study-301978985.html
SOURCE 10x Genomics, Inc